Literature DB >> 23906769

Methylphenidate restores novel object recognition in DARPP-32 knockout mice.

Charles J Heyser1, Caitlyn H McNaughton, Donna Vishnevetsky, Allen A Fienberg.   

Abstract

Previously, we have shown that Dopamine- and cAMP-regulated phosphoprotein of 32kDa (DARPP-32) knockout mice required significantly more trials to reach criterion than wild-type mice in an operant reversal-learning task. The present study was conducted to examine adult male and female DARPP-32 knockout mice and wild-type controls in a novel object recognition test. Wild-type and knockout mice exhibited comparable behavior during the initial exploration trials. As expected, wild-type mice exhibited preferential exploration of the novel object during the substitution test, demonstrating recognition memory. In contrast, knockout mice did not show preferential exploration of the novel object, instead exhibiting an increase in exploration of all objects during the test trial. Given that the removal of DARPP-32 is an intracellular manipulation, it seemed possible to pharmacologically restore some cellular activity and behavior by stimulating dopamine receptors. Therefore, a second experiment was conducted examining the effect of methylphenidate. The results show that methylphenidate increased horizontal activity in both wild-type and knockout mice, though this increase was blunted in knockout mice. Pretreatment with methylphenidate significantly impaired novel object recognition in wild-type mice. In contrast, pretreatment with methylphenidate restored the behavior of DARPP-32 knockout mice to that observed in wild-type mice given saline. These results provide additional evidence for a functional role of DARPP-32 in the mediation of processes underlying learning and memory. These results also indicate that the behavioral deficits in DARPP-32 knockout mice may be restored by the administration of methylphenidate.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DARPP-32; Memory; Methylphenidate; Novel object recognition; Ritalin

Mesh:

Substances:

Year:  2013        PMID: 23906769     DOI: 10.1016/j.bbr.2013.07.031

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

2.  The Impact of Chronic Early Administration of Psychostimulants on Brain Expression of BDNF and Other Neuroplasticity-Relevant Proteins.

Authors:  Yaarit Simchon Tenenbaum; Abraham Weizman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2015-07-08       Impact factor: 3.444

3.  Changes in C57BL6 Mouse Hippocampal Transcriptome Induced by Hypergravity Mimic Acute Corticosterone-Induced Stress.

Authors:  Alice Pulga; Yves Porte; Jean-Luc Morel
Journal:  Front Mol Neurosci       Date:  2016-12-26       Impact factor: 5.639

4.  Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in Rats.

Authors:  Lisa S Robison; Michalis Michaelos; Jason Gandhi; Dennis Fricke; Erick Miao; Chiu-Yim Lam; Anthony Mauceri; Melissa Vitale; Junho Lee; Soyeh Paeng; David E Komatsu; Michael Hadjiargyrou; Panayotis K Thanos
Journal:  Front Behav Neurosci       Date:  2017-03-28       Impact factor: 3.558

5.  Phenotypic variability between Social Dominance Ranks in laboratory mice.

Authors:  Justin A Varholick; Jeremy D Bailoo; Rupert Palme; Hanno Würbel
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

6.  Cross-disorder genetic analyses implicate dopaminergic signaling as a biological link between Attention-Deficit/Hyperactivity Disorder and obesity measures.

Authors:  Barbara Franke; Alejandro Arias Vásquez; Nina Roth Mota; Geert Poelmans; Marieke Klein; Bàrbara Torrico; Noèlia Fernàndez-Castillo; Bru Cormand; Andreas Reif
Journal:  Neuropsychopharmacology       Date:  2020-01-02       Impact factor: 8.294

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.